Thymic carcinoma of the thyroid.

A highly malignant case of intrathyroidal thymic carcinoma showing morphological and biochemical evidence identical with mediastinal thymoma is presented. A 32-year-old female, who had previously undergone total colectomy with ileo-proctostomy due to familial adenomatous polypnosis, was operated on for a tumor (3.4 x 4.5 cm) originating from the left thyroid lobe. A minute focus (diam. 0.8 cm) of papillary adenocarcinoma also existed in the upper pole of the right lobe. The main tumor was morphologically an epithelial thymoma with scanty lymphocyte intermixing and showed medullary differentiation with apparent Hassall's corpuscles. Mitosis was frequent and numerous tumor thrombi were in the subcapsular veins. Five months after the total thyroidectomy and lymph node dissection, a subcutaneous recurrence of the tumour (diam. 2.3 cm) appeared in the anterior cervical region. The cystic contents of the recurrent tumor revealed a high titer of thymosin alpha 1-Other organs, including thymus, lungs, and adrenals, had all been free of neoplastic changes clinically and radiologically for 5 months after her first admission until the local tumor recurrence.

Prevention of fatty liver and maintenance of systemic valine depletion using a newly developed dual infusion system.

BACKGROUND: Valine-depleted amino acid imbalance, while having a suppressive effect on tumor growth, may induce fatty liver. METHODS: We administered a valine-depleted total parenteral nutrition (TPN) solution by the central venous route to non-tumor-bearing rats and examined the time course of the development of fatty liver. In an attempt to prevent this condition, we administered a continuous infusion of low concentrations of valine via the portal vein simultaneously with administration of central venous valine-depleted nutrition for 4 days. RESULTS: A marked accumulation of triglyceride was observed in the liver on day 4 of the administration of valine-depleted nutrition. It is speculated that such accumulation is the cause of fatty liver. The level of valine in the peripheral blood began to decrease soon after administration was begun and resulted in a state of systemic valine deficiency. Rats given 25% or more of the valine concentration in the standard TPN solution via the portal vein simultaneously with the administration of central venous valine-depleted nutrition, had a triglyceride level similar to that of the control group. The group given 50% or less of the valine concentration had a level of valine in the peripheral blood as low as that of the valine-depleted group, indicating the maintenance of a valine-deficient state. CONCLUSION: Administration of low concentrations of valine via the portal vein simultaneous with central venous administration of valine-depleted TPN solution may prevent fatty liver.

Lymph flow and lymph node metastasis in esophageal cancer.

This paper delineates which lymph nodes should be dissected due to the high frequency of metastasis associated with different types of primarily lesions of the thoracic esophagus. In cancer involving the upper third of the esophagus (Iu), lymph flow was found to be primary from the superior mediastinal area to the cervical area; in that involving the middle third (Im), it was broadly distributed from the superior, middle, and inferior mediastinal region to the cervical and abdominal regions; and in that involving the lower third (Ei), it tended to extend from the inferior mediastinal region to the abdominal region, with single primary metastatic nodes also being noted in this area. The significance of the "top" nodes, namely, the nodes located along the right recurrent laryngeal nerve in the upper portion of the thorax, was also investigated, and it was confirmed that the prognosis for patients with metastases to both the top nodes and other nodes was unfavorable. An immunohistochemical study on mediastinal lymph flow using the anti-Su-Ps antibody demonstrated interactions between top nodes and cervical and/or thoracic nodes.

New technology for continuous intravenous infusion via the central and portal veins in the rat.

Total parenteral nutrition via the central vein is a technique used extensively in basic and clinical research. Recent research has also focused on the administration of various drugs and nutrients via the portal vein. To date, however, no technique which would permit prolonged continuous infusion simultaneously through both the central vein and the portal vein in the rat has been reported. The development of such a technique would open up new possibilities for utilizing the advantages of each of these two routes and contribute to progress in metabolic and nutritional research. To establish such a technique, the authors implemented several unique improvements such as the application of clamps to minimize bleeding during catheter insertion and an increase in the number of sutures to prevent catheter dislodgment. With these improvements, it was possible to continuously administer specified doses of infusion solution in both veins for 6 days in 156 of 158 rats (99%) in the main experiment. We herein describe the techniques used and some of the results obtained with this experimental system.

Tumor-promoting phorbol ester induces alterations of sialidase and sialyltransferase activities of JB6 cells.

Sialidase and sialyltransferase activities were studied in JB6 mouse epidermal cells before and after exposure to phorbol ester, 12-O-tetradecanoyl phorbol-13-acetate (TPA), which irreversibly induces anchorage-independent growth and tumorigenicity. JB6 cells exhibited sialidase activities toward 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid (4MU-NeuAc) and gangliosides at pH 4.5 in the particulate fraction but apparently not in the cytosol at pH 4.5 or 6.0. In JB6 cells exposed to TPA and in the anchorage-independent transformants, the sialidase activity toward 4MU-NeuAc was decreased and the activity toward gangliosides was increased compared with those in untreated JB6 cells. Immunological analysis with antisera against membrane-associated sialidases I and II revealed that plasma membrane-associated sialidase I was increased and lysosomal membrane-associated sialidase II was decreased under these conditions. TPA treatment also affected the sialyltransferase activities of JB6 cells: and elevation of the transfer activities toward asialo-orosomucoid and asialo-porcine submaxillary mucin but a reduction of GM3 and GD3 synthase activities were observed on exposure to TPA and in cells transformed by TPA to retain anchorage-independency. These results suggest that an increase in sialic acid bound to glycoproteins and a decrease in that bound to glycolipids may occur in JB6 cells exposed to TPA and in the anchorage-independent transformants.

Neoplastic alteration of a membrane-associated sialidase of rat liver.

Rat liver particulate fraction contains two types of membrane-associated and gangliosides-hydrolyzing sialidase, which have been shown to be identical to two membrane-associated sialidases of rat brain (I and II) chromatographically, immunologically and in substrate specificity. Chromatography on AH-Sepharose 4B of the membrane sialidases of rat primary hepatoma induced by 3'-methyl-4-dimethylaminoazobenzene (MeDAB) further revealed that hepatocarcinogenesis induces a marked decrease in sialidase II but no decrease in sialidase I. Using antisera against sialidases I and II of rat brain, immunoprecipitation studies of the solubilized particulate fractions of rat liver and MeDAB-hepatoma gave results similar to those obtained chromatographically. Using the same immunological technique, sialidase II but not sialidase I was found to be decreased in AH109 A hepatoma and in regenerating and fetal liver.

Biochemical and immunological studies on two distinct ganglioside-hydrolyzing sialidases from the particulate fraction of rat brain.

Ganglioside-hydrolyzing sialidase activity was solubilized from rat brain particulate fraction by using Triton X-100 plus sodium deoxycholate. When chromatographed on AH-Sepharose 4B, the solubilized activity was resolved into two peaks, which were designated sialidases I and II in order of elution. The two sialidases were purified by using sequential chromatographies on Octyl-Sepharose CL-4B, Phenyl-Sepharose CL-4B, and Sephadex G-200. Sialidase II was purified further by Mono Q-FPLC. Overall purification was 450- and 2,150-fold, for sialidases I and II, respectively. Purified sialidases I and II were maximally active at near pH 5.0 and exhibited M = 70,000 by gel filtration. Sialidase I hydrolyzed gangliosides but scarcely other substrates including 4-methylumbelliferyl-NeuAc (4MU-NeuAc). Sialidase II hydrolyzed oligosaccharides, glycoproteins, and 4MU-NeuAc although gangliosides appeared to be preferential substrates. Sialidase II cleaved GM2 much faster than sialidase I. An antibody raised in rabbits against sialidase I reacted with only sialidase I and an antibody against sialidase II reacted with only sialidase II. A subcellular distribution study suggested sialidase I in the synaptosomal membrane and sialidase II in the synaptosomal and lysosomal membranes, and this was verified by using the above antibodies.

Immunological discrimination of intralysosomal, cytosolic, and two membrane sialidases present in rat tissues.

Cytosolic sialidase was purified from rat skeletal muscle, and the purified enzyme migrated as a single band of Mr 43,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A polyclonal antibody raised against the enzyme inhibited and immunoprecipitated rat liver cytosolic sialidase as well as the muscle enzyme but failed to cross-react with the intralysosomal sialidase of rat liver and membrane sialidases I (synaptosomal) and II (lysosomal) of rat brain. The antibody against brain membrane sialidase I (anti-I) and that against sialidase II (anti-II), which could be useful to discriminate the two enzymes, did not cross-react with the intralysosomal and cytosolic sialidases of liver. Although more than 90% of liver plasma membrane sialidase was immunoprecipitated with anti-I, only 60% of liver lysosomal membrane sialidase was immunoprecipitated with anti-II, the remainder being immunoprecipitated with anti-I. In confirmation of these data, liver lysosomal membrane exhibited two peaks of ganglioside sialidase corresponding to the membrane sialidases I and II on Aminohexyl-Sepharose chromatography while only one peak of ganglioside sialidase corresponding to sialidase I was observed for liver plasma membrane. These results indicate that the four types of rat sialidase are proteins distinct from one another and that the three kinds of antisera described above are useful for discriminating these sialidases qualitatively and probably quantitatively.

Characterization of the major sialidases of various types of rat blood cells: their comparison with rat liver sialidases.

The substrate specificity and subcellular location of the major sialidases of three types of rat blood cells were characterized and compared with those of the known three types of rat liver sialidase, which have been designated intralysosomal, cytosolic, and plasma membrane-associated sialidases. Platelets and leucocytes contain mainly an acid sialidase, which is highly active towards oligosaccharides and 4MU-NeuAc, and erythrocytes possess a high level of a sialidase acting on gangliosides. A Percoll gradient centrifugation study showed that the former is located in lysosomes and the latter in plasma membrane. When the sialidase was solubilized and partially purified from erythrocyte ghosts, the enzyme was found to hydrolyze actively gangliosides but only poorly other substrates such as 4MU-NeuAc, oligosaccharides, and glycoproteins. The sialidase partially purified from rat liver membrane fraction exhibited the same substrate specificity. It is concluded that the major sialidase of platelets and leucocytes corresponds to hepatic intralysosomal sialidase while erythrocytes contain almost exclusively a ganglioside sialidase which corresponds to hepatic plasma membrane sialidase.

Effects of OK-432 activation on the sialidase activities of rat peritoneal macrophages.

Intraperitoneal treatment of rat peritoneal macrophages with OK-432 results in more than 9-fold increase in the activity of ganglioside sialidase, which seems to coincide with the appearance of a cell surface antigen, asialo-GM1. The results of subsequent studies suggest that the ganglioside sialidase is located in the plasma membrane, where the enzyme may be responsible for the formation of asialo-GM1 from GM1. In the macrophages activated with OK-432, sialidase activity toward 4-methylumbelliferyl-N-acetylneuraminic acid (4MU-NeuAc) is also increased. It appears that the 4MU-NeuAc sialidase is intralysosomal and is increased together with other acid hydrolases present in the lysosomes.

Membrane-associated sialidase of rat liver and its decrease in hepatomas.

Using the particulate fraction of tissue homogenate, plasma membrane-associated sialidase was assayed at pH 4.5 with bovine brain mixed gangliosides as the substrate. The activity was lower in rat hepatoma induced by 3'-methyl-4-dimethylaminoazobenzene (MeDAB) and transplantable AH-109A rat hepatoma than in normal rat liver. The enzyme was almost quantitatively solubilized from liver particulate fraction by using 0.5% (w/v) sodium deoxycholate plus 0.2% (w/v) Triton X-100. When chromatographed on DEAE-cellulose, the solubilized activity emerged as a single peak. The enzyme thus obtained was maximally active at pH 4.5, and readily hydrolyzed mixed gangliosides but was less active toward 4-methylumbelliferyl-alpha-N-acetylneuraminic acid, 3'-sialyllactose and fetuin. The corresponding enzyme from MeDAB-induced hepatoma was indistinguishable from the liver enzyme in terms of ease of solubilization, pH-activity relationship, chromatographic behavior and substrate preference. It therefore appears that the plasma membrane-associated sialidase of hepatomas differs from that of liver only in the tissue level of activity.